Replies to post #68208 on Biotech Values

[gym gravity]

thanks dew, does anyone disagree with this number:

"
About one in four of 370 publicly held U.S. biotechnology companies has less than six months' cash on hand, according to the Biotechnology Industry Organization, a Washington-based trade group.

``Disarray'' among biotech companies in a tough economic climate works to Amgen's advantage, said Jordan Schreiber, managing director of BlackRock Investment Management's Healthcare Fund, which holds 4.8 million shares. Acquisitions could help Amgen reignite sales and broaden its product pipeline, he said in a telephone interview.

"

[rkrw]

Abgenix and there was a phosphate binder company, I forget the name. Long been rumored amgn would buy amag.

[pharmaclown35]

what do you think about Amgen buying someone like genzyme? is that crazy?

also, couldn't gilead buy vertex or another HCV company. they're not in HCV, but they're huge in HIV . so doesn't that make sense to do a deal like that?

i still think all these mid-cap HCV companies, Intermune, Pharmasset, Anadys, Idenix will all get acquired by Roche, schering, or another large pharma in the next 12-18 mths.